Connect Biopharma Files 8-K for Regulation FD Disclosure
Ticker: CNTB · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1835268
Sentiment: neutral
Topics: disclosure, regulation-fd
Related Tickers: CNTB
TL;DR
CNTB filed an 8-K for a Reg FD disclosure on 9/16/25. No other material info.
AI Summary
Connect Biopharma Holdings Ltd. filed an 8-K on September 16, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself. The company's principal executive offices are located in San Diego, California.
Why It Matters
This filing indicates Connect Biopharma is making a public disclosure under Regulation FD, which ensures fair disclosure of material information to all investors.
Risk Assessment
Risk Level: low — The filing is a standard disclosure and does not report any new material events, financial changes, or significant business developments.
Key Players & Entities
- Connect Biopharma Holdings Ltd (company) — Registrant
- September 16, 2025 (date) — Date of Report
- San Diego, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 16, 2025.
Where are Connect Biopharma Holdings Ltd.'s principal executive offices located?
Connect Biopharma Holdings Ltd.'s principal executive offices are located at 3580 Carmel Mountain Road, Suite 200, San Diego, California, 92130.
What is the company's standard industrial classification code?
The company's standard industrial classification code is 2834, for Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2025-09-16 09:02:18
Key Financial Figures
- $0.000174 — registered Ordinary Shares, par value $0.000174 per share CNTB The Nasdaq Global Market
Filing Documents
- cntb-20250916.htm (8-K) — 24KB
- 0001835268-25-000056.txt ( ) — 140KB
- cntb-20250916.xsd (EX-101.SCH) — 2KB
- cntb-20250916_lab.xml (EX-101.LAB) — 22KB
- cntb-20250916_pre.xml (EX-101.PRE) — 13KB
- cntb-20250916_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Barry D. Quart, Pharm.D., Chief Executive Officer and Director of Connect Biopharma Holdings Limited (the "Company"), purchased a total of 224,034 shares of the Company in a series of transactions occurring between September 2024 and September 2025. David Szekeres, President of the Company, purchased a total of 215,739 shares of the Company in a series of transactions occurring between November 2024 and September 2025. All purchases described in this Item 7.01 were made in compliance with the Company's Insider Trading Compliance Policy, as in effect at the applicable times. The information in Item 7.01 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no obligation to publicly update any information furnished in this Item 7.01, whether because of future events or otherwise.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CONNECT BIOPHARMA HOLDINGS LIMITED Date: September 16, 2025 By: /s/ David Szekeres Name: David Szekeres Title: President